Bausch Health reported continued robust performance with 10 consecutive quarters of revenue and adjusted EBITDA growth, driven by strong gains in its Solta and Salix business segments.

• Q3 revenue increased 7% year-over-year to $2.681 billion, with organic growth of 5%.
• Adjusted EBITDA reached $986 million, reflecting an 8% year-over-year rise, and 18% growth when excluding an $81 million R&D charge.
• The Solta division saw outstanding growth of 25%, while Salix reported 12% revenue growth, fueled by strong performance in flagship products like Xifaxan.
• The company reduced its debt by approximately $600 million, reinforcing its financial stability and allowing for raised full-year guidance across revenue, adjusted EBITDA, and cash flow.
• Operational cash flow was steady at $508 million, demonstrating solid cash management despite working capital timing impacts.